Ken Griffin Jasper Therapeutics, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.42 - $0.93 $47,388 - $104,930	112,829 Added 144.05%	191,155 $151,000
Q3 2023 Nov 14, 2023	SELL	$0.68 - $1.54 $916,433 - $2.08 Million	-1,347,696 Reduced 94.51%	78,326 $54,000
Q2 2023 Aug 14, 2023	SELL	$1.19 - $1.79 $3.08 Million - $4.63 Million	-2,587,016 Reduced 64.47%	1,426,022 $1.95 Million
Q1 2023 May 15, 2023	BUY	$1.48 - $2.74 $1.3 Million - $2.41 Million	877,998 Added 28.01%	4,013,038 $7.26 Million
Q4 2022 Feb 14, 2023	BUY	$0.46 - $8.9 $15,191 - $293,913	33,024 Added 1.06%	3,135,040 $1.5 Million
Q3 2022 Nov 14, 2022	BUY	$0.08 - $22.6 $10,321 - $2.92 Million	129,013 Added 4.34%	3,102,016 $2.45 Million

5.63M

Ticker JSPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,073,300
Market Cap $807M
Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a techniqu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.